Tissue Repair (TRP) Stock Overview
A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TRP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Tissue Repair Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.30 |
| 52 Week High | AU$0.37 |
| 52 Week Low | AU$0.17 |
| Beta | 0.38 |
| 1 Month Change | -7.58% |
| 3 Month Change | 10.91% |
| 1 Year Change | 19.61% |
| 3 Year Change | 17.31% |
| 5 Year Change | n/a |
| Change since IPO | -56.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRP | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -3.2% | 1.3% | -1.6% |
| 1Y | 19.6% | -32.6% | 3.8% |
Return vs Industry: TRP exceeded the Australian Biotechs industry which returned -34% over the past year.
Return vs Market: TRP exceeded the Australian Market which returned 6.1% over the past year.
Price Volatility
| TRP volatility | |
|---|---|
| TRP Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 19.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: TRP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: TRP's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Tony Charara | tissuerepair.com.au |
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures.
Tissue Repair Ltd Fundamentals Summary
| TRP fundamental statistics | |
|---|---|
| Market cap | AU$18.44m |
| Earnings (TTM) | -AU$4.24m |
| Revenue (TTM) | AU$2.63m |
Is TRP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRP income statement (TTM) | |
|---|---|
| Revenue | AU$2.63m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.63m |
| Other Expenses | AU$6.87m |
| Earnings | -AU$4.24m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.07 |
| Gross Margin | 100.00% |
| Net Profit Margin | -160.96% |
| Debt/Equity Ratio | 0% |
How did TRP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/14 02:33 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tissue Repair Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Power | Morgans Financial Limited |
| Iain Wilkie | Morgans Financial Limited |